CA
NZ
UK
AU
IND
US
Evolent Health, Inc. (NYSE:EVH)'s second quarter combined sharply higher revenue and Adjusted EBITDA with a net loss, as its Performance Suite segment grew and the company raised its full-year 2026 outlook. Co-Founder and Chief Executive Officer Seth Blackley said the company's results, updated 2026 …
Sarepta Therapeutics, Inc. (NASDAQ:SRPT)'s second quarter combined continued operating profitability with a sharp decline in total revenue, driven primarily by lower sales of its gene therapy Elevidys following prior safety events and a label change restricting its use to ambulatory patients. New Chief Executive …
● Non-GAAP earnings per share were $1.62, up from $1.37.
● The net loss widened to US$120.4 million from US$82.5 million.
● Aardvark terminated the Phase 3 HERO trial and its extension in June.
● The charge reduces earnings by $0.11 per diluted share.
● Daily hot flashes fell by 8.8 events with ABCL635 versus 3.5 with placebo.
● Five patients were treated in the quarter, with revenue recognised for four.
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. Capricor announced on August 24 that the FDA extended the PDUFA date for deramiocel, a cell therapy for Duchenne muscular …
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. C4 Therapeutics develops targeted protein degraders, and its lead drug cemsidomide is an oral molecular glue degrader of IKZF1 and …
Please wait processing your request...